Antibiotic-induced gut microbiota disruption during human endotoxemia: A randomised controlled study

Gut

Volumn 66, Issue 9, 2017, Pages 1623-1630

  Lankelma, Jacqueline M ^a   Cranendonk, Duncan R ^a   Belzer, Clara ^b   De Vos, Alex F ^a   De Vos, Willem M ^b,c   Van Der Poll, Tom ^a   Wiersinga, W Joost ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antibiotics; Endotoxin; Enteric Bacterial Microflora; Immune Response; Sepsis

Indexed keywords

CIPROFLOXACIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; METRONIDAZOLE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; VANCOMYCIN; VASCULAR CELL ADHESION MOLECULE 1; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM; BIFIDOBACTERIUM; BLOOD CLOTTING; BLOOD SAMPLING; CELL ACTIVATION; COMMUNITY STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TOLERANCE; ENDOTHELIUM CELL; ENDOTOXEMIA; ESCHERICHIA COLI; FECES ANALYSIS; FIBRINOLYSIS; HUMAN; INNATE IMMUNITY; INTERVENTION STUDY; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE; LEUKOCYTE; MALE; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; NEUTROPHILIA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROSEBURIA; STREPTOCOCCUS PNEUMONIAE; DRUG EFFECTS; DRUG MONITORING; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY; SEPSIS; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG MONITORING; ENDOTOXEMIA; ESCHERICHIA COLI; GASTROINTESTINAL MICROBIOME; HEALTHY VOLUNTEERS; HUMANS; IMMUNITY, INNATE; KLEBSIELLA PNEUMONIAE; MALE; METRONIDAZOLE; SEPSIS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84977496449     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-312132     Document Type: Article

References (46)

1. Kamada N, Seo SU, Chen GY, et al. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013;13:321-35.
2. Schuijt TJ, van der Poll T, de Vos WM, et al. The intestinal microbiota and host immune interactions in the critically ill. Trends Microbiol 2013;21:221-9.
3. Debast SB, Bauer MP, Kuijper EJ, et al. European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20(Suppl 2):1-26.
4. Li Q, Wang C, Tang C, et al. Therapeutic modulation and reestablishment of the intestinal microbiota with fecal microbiota transplantation resolves sepsis and diarrhea in a patient. Am J Gastroenterol 2014;109:1832-4.
5. Li Q, Wang C, Tang C, et al. Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: A case report. Crit Care 2015;19:37.
6. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. Jama 2009;302:2323-9.
7. Korpela K, Salonen A, Virta LJ, et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat Commun 2016;7:10410.
8. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011;108(Suppl 1):4554-61.
9. Bernard H, Desseyn JL, Bartke N, et al. Dietary pectin-derived acidic oligosaccharides improve the pulmonary bacterial clearance of Pseudomonas aeruginosa lung infection in mice by modulating intestinal microbiota and immunity. J Infect Dis 2015;211:156-65.
10. Clarke TB. Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands. Infect Immun 2014;82:4596-606.
11. Clarke TB, Davis KM, Lysenko ES, et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010;16:228-31.
12. Deshmukh HS, Liu Y, Menkiti OR, et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat Med 2014;20:524-30.
13. Khosravi A, Yáñez A, Price JG, et al. Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host Microbe 2014;15:374-81.
14. Schuijt TJ, Lankelma JM, Scicluna BP, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 2016;65:575-83.
15. Balmer ML, Schürch CM, Saito Y, et al. Microbiota-derived compounds drive steady-state granulopoiesis via MyD88/TICAM signaling. J Immunol 2014;193:5273-83.
16. Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014;20:159-66.
17. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: A novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013;13:260-8.
18. Andreasen AS, Krabbe KS, Krogh-Madsen R, et al. Human endotoxemia as a model of systemic inflammation. Curr Med Chem 2008;15:1697-705.
19. Lowry SF. Human endotoxemia: A model for mechanistic insight and therapeutic targeting. Shock 2005;24(Suppl 1):94-100.
20. Stegenga ME, van der Crabben SN, Blümer RM, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 2008;112:82-9.
21. van Zoelen MA, Vogl T, Foell D, et al. Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. Am J Respir Crit Care Med 2009;180:1098-106.
22. van den Bogert B, Erkus O, Boekhorst J, et al. Diversity of human small intestinal Streptococcus and Veillonella populations. FEMS Microbiol Ecol 2013;85:376-88.
23. Salonen A, Nikkilä J, Jalanka-Tuovinen J, et al. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: Effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J Microbiol Methods 2010;81:127-34.
24. Branger J, van den Blink B, Weijer S, et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003;101:4446-8.
25. Lemaire LC, de Kruif MD, Giebelen IA, et al. Differential dose-dependent effects of prednisolone on shedding of endothelial adhesion molecules during human endotoxemia. Immunol Lett 2008;121:93-6.
26. Renckens R, Weijer S, de Vos AF, et al. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. Arterioscler Thromb Vasc Biol 2004;24:483-8.
27. de Vos AF, Pater JM, van den Pangaart PS, et al. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol 2009;183:533-42.
28. van 't Veer C, van den Pangaart PS, van Zoelen MA, et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 2007;179:7110-20.
29. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862-74.
30. Wiersinga WJ, van't Veer C, van den Pangaart PS, et al. Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit Care Med 2009;37:569-76.
31. Jakobsson HE, Jernberg C, Andersson AF, et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS ONE 2010;5:e9836.
32. Rashid MU, Zaura E, Buijs MJ, et al. Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods. Clin Infect Dis 2015;60(Suppl 2):S77-84.
33. Rajili-Stojanovi M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev 2014;38:996-1047.
34. Ungaro R, Bernstein CN, Gearry R, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: A meta-analysis. Am J Gastroenterol 2014;109:1728-38.
35. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011;60:49-54.
36. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012;488:178-84.
37. Shimizu K, Ogura H, Hamasaki T, et al. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci 2011;56:1171-7.
38. Shimizu K, Ogura H, Tomono K, et al. Patterns of Gram-stained fecal flora as a quick diagnostic marker in patients with severe SIRS. Dig Dis Sci 2011;56:1782-8.
39. Prescott HC, Dickson RP, Rogers MA, et al. Hospitalization Type and Subsequent Severe Sepsis. Am J Respir Crit Care Med 2015;192:581-8.
40. Brandl K, Plitas G, Mihu CN, et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 2008;455:804-7.
41. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
42. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:139-48.
43. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013;500:541-6.
44. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207-14.
45. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110:3507-12.
46. Takao K, Miyakawa T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2015;112:1167-72.